Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2643
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBruynesteyn, K-
dc.contributor.authorVAN DER HEIJDE, Desiree-
dc.contributor.authorBoers, M-
dc.contributor.authorVerhoeven, A-
dc.contributor.authorBoonen, A-
dc.contributor.authorVan der Linden, S-
dc.date.accessioned2007-11-15T15:05:58Z-
dc.date.available2007-11-15T15:05:58Z-
dc.date.issued2002-
dc.identifier.citationARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 47(5). p. 532-536-
dc.identifier.issn0004-3591-
dc.identifier.urihttp://hdl.handle.net/1942/2643-
dc.description.abstractObjective. In rheumatoid arthritis (RA) in the context of a drug trial, prevention of erosions in undamaged joints is often considered more important than prevention of progression in already damaged joints, although a clear rationale is lacking. The aim of this study is to evaluate the relative contribution of separate components of the erosion score of the modified Sharp/van der Heijde method in early RA. Methods. Different aspects of erosive damage were evaluated by their ability to discriminate between the 2 treatments in an early RA trial (the COBRA trial). Results. The contribution of progression of already eroded joints to the total erosion score clearly increased during the 1.5 years of the trial. When the periods 0-28, 28-56, and 56-80 weeks were analyzed separately, the erosion score showed a significant difference between the groups in the first 2 periods (P < 0.0001, P < 0.03, and P < 0.64, respectively). Similar differences were seen in rates of progression in previously eroded joints (P = 0.005, P = 0.003, P = 0.35). On the other hand, rates of progression in newly eroded joints showed no significant difference between the 2 treatment groups in the second and third period (P < 0.0001, P < 0.16, P < 0.87). Analyses on joint and patient level showed analogous results. Conclusion. Subanalyses on progression rates in noneroded joints and already eroded joints can provide additional information. However, important information and discriminative strength may be lost when assessment is limited to the development of erosions in undamaged joints.-
dc.language.isoen-
dc.publisherWILEY-LISS-
dc.subject.otherrheumatoid arthritis; radiographs; erosions; progression-
dc.titleContribution of progression of erosive damage in previously eroded joints in early rheumatoid arthritis trials: COBRA trial as an example-
dc.typeJournal Contribution-
dc.identifier.epage536-
dc.identifier.issue5-
dc.identifier.spage532-
dc.identifier.volume47-
local.format.pages5-
local.bibliographicCitation.jcatA1-
dc.description.notesUniv Maastricht, Maastricht, Netherlands. Limburgs Univ Ctr, Diepenbeek, Belgium. Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.Bruynesteyn, K, Univ Hosp Maastricht, Dept Internal Med, Div Rheumatol, POB 5800, NL-6202 AZ Maastricht, Netherlands.-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcatA1-
dc.identifier.doi10.1002/art.10654-
dc.identifier.isi000178714400012-
item.fulltextNo Fulltext-
item.fullcitationBruynesteyn, K; VAN DER HEIJDE, Desiree; Boers, M; Verhoeven, A; Boonen, A & Van der Linden, S (2002) Contribution of progression of erosive damage in previously eroded joints in early rheumatoid arthritis trials: COBRA trial as an example. In: ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 47(5). p. 532-536.-
item.contributorBruynesteyn, K-
item.contributorVAN DER HEIJDE, Desiree-
item.contributorBoers, M-
item.contributorVerhoeven, A-
item.contributorBoonen, A-
item.contributorVan der Linden, S-
item.accessRightsClosed Access-
item.validationecoom 2003-
crisitem.journal.issn0004-3591-
Appears in Collections:Research publications
Show simple item record

SCOPUSTM   
Citations

10
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

11
checked on May 7, 2024

Page view(s)

70
checked on Nov 7, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.